-
Mashup Score: 22
– First CRISPR gene-editing filings to be accepted for review by FDA – – FDA grants Priority Review for severe sickle cell disease (SCD) and Standard Review for transfusion-dependent beta thalassemia (TDT) – – PDUFA target action date of December 8, 2023 , for SCD and March 30, 2024 , for TDT –
Source: CRISPR TherapeuticsCategories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 13
– Both trials met the primary and key secondary endpoints at the pre-specified interim analysis – – Data continue to demonstrate transformative and durable benefit – – Safety profile consistent with busulfan conditioning and autologous hematopoietic stem cell transplant – BOSTON & ZUG,
Source: CRISPR TherapeuticsCategories: Future of Medicine, Latest HeadlinesTweet-
Our teams and investigators shared new clinical data on our investigational gene-edited therapy for the treatment of sickle cell disease and beta thalassemia at the @EHA_Hematology 2023 Annual Congress. Learn more: https://t.co/Al7P16Ia35 https://t.co/QSu9xjwtI4
-
-
Mashup Score: 13CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results | CRISPR Therapeutics - 12 month(s) ago
-Regulatory submissions complete for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, in the U.S. for transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD)- -EU and U.K. submissions validated by European Medicines Agency (EMA) and the Medicines and
Source: CRISPR TherapeuticsCategories: Future of Medicine, Latest HeadlinesTweet-
Today, we announced our first quarter earnings results. Read more about our recent highlights and outlook: https://t.co/TlSyopci8x https://t.co/cOr83yRWoK
-
-
Mashup Score: 1International Thalassaemia Day 2023 - TIF - 1 year(s) ago
The Theme May 8, 2023 is International Thalassaemia Day. The theme of the event this year is “Strengthening Education to Bridge the Thalassaemia Care Gap”. By maximizing the knowledge and skills of every person affected by thalassaemia and the people who care for them, we can achieve positive changes in health behaviours, health outcomes and quality of life, and reduce the disease burden for…
Source: TIFCategories: Future of Medicine, Latest HeadlinesTweet-
Today is #WorldThalassemiaDay. This year's theme is “Strengthening Education to Bridge the Thalassemia Care Gap,” which focuses on ways to support those affected by this condition through education and other resources. Click here for more info: https://t.co/sZAtUUDiLZ https://t.co/iRMbYk9Jdk
-
-
Mashup Score: 6HHS Office of Minority Health - National Minority Health Month - 1 year(s) ago
#NationalMinorityHealthMonth
Source: www.minorityhealth.hhs.govCategories: Future of Medicine, Latest HeadlinesTweet-
#NationalMinorityHealthMonth brings awareness to the disproportionate burden of illness and health-related challenges on underserved communities and encourages action to build greater #healthequity. Learn more here: https://t.co/RIjlxLVESy https://t.co/xnjFBxpDca
-
-
Mashup Score: 21Presentations | CRISPR Therapeutics - 1 year(s) ago
The Investor Relations website contains information about CRISPR Therapeutics’s business for stockholders, potential investors, and financial analysts.
Source: CRISPR TherapeuticsCategories: Future of Medicine, Latest HeadlinesTweet-
Yesterday at the @AACR Annual Meeting, Dr. Jon Terrett, @CRISPRTX Head of Research, presented preclinical data on next generation CRISPR/Cas9-engineered allogeneic CAR T cells for treatment of liquid and solid tumors. Learn more: https://t.co/wlvbXMmRFj #AACR23 #CRISPRTX https://t.co/9hnZ8nfjwn
-
-
Mashup Score: 7
-EU and UK filings completed in 2022; submissions validated by EMA and MHRA and the review procedure has begun as of January 2023- BOSTON and ZUG, Switzerland, April 3, 2023 – CRISPR Therapeutics and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the completion of the rolling
Source: CRISPR TherapeuticsCategories: Future of Medicine, Latest HeadlinesTweet-
We are pleased to announce that we’ve completed the submission of our Biologics License Applications (BLAs) to the U.S. FDA for our potential treatment for sickle cell disease and beta thalassemia. Learn more: https://t.co/u3dNx9DC80 https://t.co/xJXBYLwnO8
-
-
Mashup Score: 4CRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting | CRISPR Therapeutics - 1 year(s) ago
ZUG, Switzerland and BOSTON , March 14, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation of preclinical data at the American Association for
Source: CRISPR TherapeuticsCategories: Future of Medicine, Latest HeadlinesTweet-
Today, we announced the acceptance of an oral presentation at the upcoming American Association for Cancer Research 2023 Annual Meeting. Learn more here: https://t.co/IQSP1GUAVj #AACR23 https://t.co/yFgIYLYKfO
-
-
Mashup Score: 12CRISPR Therapeutics Announces Transition of Chief Financial Officer | CRISPR Therapeutics - 1 year(s) ago
ZUG, Switzerland and BOSTON , March 13, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announces the hiring and appointment of Raju Prasad , Ph.D., as Chief Financial Officer,
Source: CRISPR TherapeuticsCategories: Future of Medicine, Latest HeadlinesTweet-
We’re excited to welcome Raju Prasad, Ph.D., as Chief Financial Officer of @CRISPRTX. Dr. Prasad brings in-depth knowledge of the cell and gene therapy space along with extensive experience in capital markets. Learn more: https://t.co/AW7aizW2oW https://t.co/YIuMfvCpmT
-
-
Mashup Score: 2Chuck - Renal Cell Carcinoma - 1 year(s) ago
Facing an Unexpected Challenge Renal Cell Carcinoma Chuck’s Story Chuck is a self-professed type A personality. An ‘Irish Catholic kid from Boston,’ he reached the top of the corporate ladder in a demanding position as Vice President of Business Operations with the National Fire Protection Association. Naturally, he…
Source: CRISPRCategories: Future of Medicine, Latest HeadlinesTweet-
We're inspired by people like Chuck, fighting every day for the opportunity to celebrate more of life's big moments. Read his story: https://t.co/XBR2pOWlNp #RenalCellCarcinoma #KidneyCancerAwarenessMonth #OrangeUp https://t.co/JnOAPQ8knO
-
We are pleased to announce that FDA has accepted our biologics license applications for our potential treatment for sickle cell disease and transfusion-dependent beta thalassemia. Our application for sickle cell disease has been granted priority review: https://t.co/pu6iOOi7lp https://t.co/0KRCC9Xjwi